Evaluating Future IVD Plasma P-Tau 181 and ApoE4 Immunoassays for Rule Out of Amyloid Pathology in a Multi-Center Study Reflective of Routine Clinical Practice (P7-3.017)
This study investigates the clinical performance of plasma pTau181 in combination with plasma ApoE4 as a potential IVD to detect amyloid pathology from a broad population as seen in routine clinical practice.
Authors
- Monica Crane (ORCID: https://orcid.org/0000-0001-8030-5506)
- Sayuri Hortsch
- Craig Ritchie (ORCID: https://orcid.org/0000-0002-6202-6906)
- Jonathan Liss
- Stephanie Buchman Rutrick (ORCID: https://orcid.org/0000-0003-1165-6614)
- Merçé Boada (ORCID: https://orcid.org/0000-0003-2617-3009)
- Jeffrey A. Norton (ORCID: https://orcid.org/0000-0003-4762-9466)
- Kevin Hanson (ORCID: https://orcid.org/0000-0002-8021-4652)
- Imke Kirste
- Frederiksen Kristian Steen
- Marc Suárez‐Calvet (ORCID: https://orcid.org/0000-0002-2993-569X)
- Clara Quijano‐Rubio (ORCID: https://orcid.org/0000-0001-9050-3282)
- David Watson
- Kelley Yokum
- Sheila Baez-Torres
Institutions
- Roche (Switzerland) (CH)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Brain (Germany) (DE)
- Columbus Center (US)
- Dementia UK (GB)
- Fundació ACE (ES)
- Barcelonaβeta Brain Research Center (ES)
- Genesis Medical Center (US)
- Chart Industries (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210490
- Citations
- 1
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 2.63